A Look at Allergan's Courtship of Bay Area's Tobira
Allergan Inc. repeatedly revised and sweetened its offer for Tobira Therapeutics Inc. before sealing a deal to acquire the maker of a potential treatment for liver disease, a sign of the power startup drugmakers have to drive up acquisition prices.
From its starting bid to the final offer, and despite the failure of a trial in between, Allergan raised the value of its offer by $145 million, according to a regulatory filing by the company on Monday. The Tobira acquisition brought Allergan an experimental drug for a liver disease known as NASH, one of biotechnology’s hottest areas with a potentially huge patient population.
From its starting bid to the final offer, and despite the failure of a trial in between, Allergan raised the value of its offer by $145 million, according to a regulatory filing by the company on Monday. The Tobira acquisition brought Allergan an experimental drug for a liver disease known as NASH, one of biotechnology’s hottest areas with a potentially huge patient population.